BIND Hires New CEO, Raises $11M

Xconomy Boston — 

BIND Biosciences, a Cambridge, MA-based developer of nanoparticle drugs, says today that it has appointed Scott Minick as its president and CEO. Minick was previously a managing director of ARCH Venture Partners, a major investor in BIND. The company also told Mass High Tech that it has raised $11 million in a Series C round of financing, bringing its total venture financing raised to $29.5 million.